BRD Media Medical Website Design Review: Top HIPAA Compliant Webs – The National Law Review
Weaponized ARTEX Pen Testing Framework Used in Attacks on Healthcare Orgs – The HIPAA Journal
Weaponized ARTEX Pen Testing Framework Used in Attacks on Healthcare Orgs
Threat actors are using a weaponized version of the ARTEX open source penetration testing tool to attack organizations in a variety of sectors, including healthcare, according to a November 13, 2026, Federal Bureau of Investigation (FBI) Flash Advisory. ARTEX is an agentic LLM-driven framework that was developed as an autonomous defensive penetration testing tool for security assessments. The original creator released the tool on GitHub in July 2026; however, the project was shut down in October 2026 after the creator learned that it had been weaponized by threat actors.
According to the FBI, more than 1,600 publicly exposed ARTEX Console instances have been identified, and the framework continues to proliferate through community forks. The FBI expects there are many more deployments on private networks and behind firewalls. The weaponized ARTEX framework has been used by malicious actors since at least August 2026 to automate and chain multiple attack phases simultaneously, from reconnaissance to data exfiltration. The weaponized tool allows multiple attack phases to be conducted at machine speed, significantly increasing attack velocity and expanding operational scale.
The FBI has identified victims in multiple industry sectors, including financial services, government, technology, defense, semiconductor, energy, healthcare, manufacturing, legal, and telecommunications. The framework was used in the recent ConnectWise Cloud Backup supply chain compromise that affected more than 2,250 downstream tenants. The FBI warns that ARTEX is particularly effective at identifying and exploiting security vulnerabilities in peripheral systems, including partner and supplier portals, employee applications, mobile backends, legacy services, and applications used by different business units, which typically receive less security attention than key systems.
While the tool can generate high volumes of forensically noisy traffic that may be flagged by security solutions, the speed at which attacks are conducted makes it challenging to identify an attack in progress in time to thwart the attacker’s objectives. The Flash Advisory provides observed Tactics, Techniques, and Procedures (TTPs) and Indicators of Compromise (IoCs). Recommended mitigations include reducing the external attack surface, hardening identity and access controls, and strengthening application protections.
“With the public release of ARTEX, threat actors have changed the tempo. When an AI-driven framework chains reconnaissance, exploitation, and privilege escalation in under a few hours, the threat actor no longer must be skilled. They only have to be pointed in the right direction using a toolkit pre-tuned for their nefarious activities,” explained Morey J. Haber, Chief Security Advisor at Atlanta, Georgia-based privilege-centric identity security provider BeyondTrust. “Consider that ARTEX can identify exposed cloud credentials, trust relationships between vendors, and automation pipelines. This is an identity and privilege problem, not a malware problem. ARTEX is not breaking in so much as logging in with keys it finds lying around, including machine identities and service accounts that nobody is monitoring or that have been forgotten about. And since it maps trust between organizations, your risk is only as strong as your weakest supplier. Put simply, the blast radius extends well beyond your own perimeter.”
The post Weaponized ARTEX Pen Testing Framework Used in Attacks on Healthcare Orgs appeared first on The HIPAA Journal.
BRD Media Medical Website Design Review: Top HIPAA Compliant Website Guides Skip Google Analytics and the Meta Pixel – EIN News
Data Breaches Announced by LifeTouch Health; MPOWERHealth; Geisinger
Data breaches have been announced by the Arkansas hospice operator LifeTouch Health, the Texas-based healthcare company MPOWERHealth Holdings, and the Pennsylvania-based healthcare system Geisinger.
LifeTouch Health
LifeTouch Health, formerly known as Arkansas Hospice Inc., the largest nonprofit hospice and palliative care provider in Arkansas, has announced that it experienced a cybersecurity incident in March of this year that exposed personal and protected health information. The incident was identified on or around March 12, 2026, when it experienced a network disruption. Steps were taken to secure its systems, and third-party digital forensics experts were engaged to investigate the activity. They confirmed that an unauthorized third party accessed its network and certain stored information for a limited time and may have copied files.
The data review has recently been completed, and the incident has been reported to the HHS’ Office for Civil Rights as involving the protected health information of 38,629 individuals. Data potentially compromised in the incident included names in combination with dates of birth, diagnoses, treatment information, and/or Social Security numbers.
MPOWERHealth Holdings
MPOWERHealth Holdings, an Addison, Texas-based provider of musculoskeletal care solutions and value-based healthcare management, has notified the California Attorney General about a cybersecurity incident that was identified on or around June 26, 2025. Immediate action was taken to secure its network, and the forensic investigation confirmed that an unauthorized third party gained access to a limited portion of its network.
Files on the compromised parts of its network have been reviewed, and on October 20, 2026, MPOWERHealth confirmed that protected health information had been exposed. The types of data involved varied from individual to individual and may have included names in combination with some or all of the following: date of birth, Social Security Number, driver’s license number, state/government ID, financial account information, medical information, and health insurance information.
Regulators have been notified, and individual notification letters started to be mailed to the affected individuals on November 13, 2026. MPOWERHealth said it continually evaluates and modifies its data security and privacy practices and internal controls and will continue to do so. The California Attorney General does not publish information on the number of affected individuals, and the incident has yet to be added to the HHS’ Office for Civil Rights breach portal, so it is currently unclear how many individuals have been affected.
Geisinger
Geisinger, a Danville, Pennsylvania-based integrated healthcare system, has started notifying a limited number of individuals about a recent cybersecurity incident that potentially resulted in the theft of some of their protected health information. According to its November 16, 2026, data breach notice, the incident affects fewer than 2,000 individuals. Suspicious activity was identified within an employee’s email account on August 20, 2026. Immediate action was taken to secure the account, and cybersecurity professionals were engaged to investigate the incident and implement additional cybersecurity measures to better protect its email system from unauthorized access.
The account has been reviewed and was found to contain patient names, dates of birth, medical record numbers, admission/service dates, and insurance carrier names. No medical information, financial information, or Social Security numbers were exposed, and no misuse of data has been identified; however, out of an abundance of caution, the affected individuals have been offered complimentary identity theft protection services.
The post Data Breaches Announced by LifeTouch Health; MPOWERHealth; Geisinger appeared first on The HIPAA Journal.
FDA Seeks Feedback on Risks from Autonomous/Remote Teleoperation Medical Devices – The HIPAA Journal
FDA Seeks Feedback on Risks from Autonomous/Remote Teleoperation Medical Devices
The U.S. Food and Drug Administration (FDA) is seeking feedback on the benefits and risks of implementing autonomous and remotely operated medical devices in healthcare and has published a paper – Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities – to start a discussion. The FDA states that the paper does not constitute draft or final guidance, and is intended to inform future FDA policy development responsive to innovation, while maintaining device safety and effectiveness.
Currently, the FDA has yet to issue U.S. marketing authorization for either fully autonomous or teleoperated robotic devices but states that it is committed to ensuring that patients continue to have access to safe, secure, and effective medical devices. The FDA has already authorized robotically assisted surgical devices for use in the United States, and innovations in artificial intelligence and machine learning, along with advances in connectivity, mean autonomous and remote teleoperation capabilities could potentially be utilized to deliver care to patients more effectively. The FDA is looking to open up a conversation about these emerging capabilities to help inform future policy decisions and is seeking feedback on what it describes as “increasingly complex considerations” concerning device safety and effectiveness.
The FDA is seeking feedback specifically on autonomy rather than automaticity. The latter concerns following strict, programmed, and completely predictable rules, whereas autonomy involves making decisions in response to changing external conditions, which increases risk. The discussion is intended to cover all degrees of autonomy, such as performing discrete tasks while a human is in charge up to full autonomy, and remotely teleoperated devices, which can be controlled by a clinician who is not present in the operating room or other care setting.
While the FDA seeks information on robotic surgical systems, the paper covers a wide range of devices and systems capable of performing diagnostic, therapeutic, or rehabilitative tasks on human anatomy, such as positioning and/or controlling instruments and imaging tools, and open, minimally invasive, non-invasive, or endoluminal surgical or interventional procedures. The FDA is seeking feedback from stakeholders with experiences and perspectives on the benefits and risks of using increasingly autonomous robotic device systems, to help ensure that they can be regulated to ensure their safety and effectiveness throughout the total product life cycle.
The benefits are numerous and include more consistent and repeatable results, reducing the risk of adverse events through human imprecision or lack of experience, more effective planning, and easing the strain on clinicians. There are naturally risks associated with autonomous devices, as AI-powered systems have shown that they are also capable of error, may perform poorly in situations outside of their training data, or may drift over time. In the case of autonomous surgical devices, there are risks associated with unexpected or irregular anatomy, their ability to control bleeding, and must allow clinicians to rapidly take control if the necessity arises. Risk also has the potential to increase with the level of autonomy.
Remote teleoperation has tremendous benefits, one of the most important being to expand the treatments available to patients in underserved areas. Highly skilled surgeons could remotely perform procedures in hospitals in underserved areas, rather than requiring patients to travel long distances for treatment, allowing time-critical procedures to be provided rapidly. Connectivity issues are a significant risk, as is the ability to manage complications remotely. The FDA specifically requests feedback on how quickly procedures can switch from remote operation to manual, whether local expertise is required, and how fast a patient can be escalated or transferred.
Cybersecurity is a key concern. Connected devices, including autonomous and remotely operated medical devices, are cyber devices under Section 524B of the FD&C Act. As such, the FDA’s cybersecurity requirements for premarket submissions will apply. While not specifically mentioned in the discussion paper, these include an SBOM, patch management, and postmarket vulnerability monitoring and disclosure. Autonomy increases the threat surface, and a cybersecurity threat could compromise a system’s functionality, availability, and data integrity. Further, as users take a more supervisory role, they may not have sufficient bandwidth to address cybersecurity vulnerabilities.
Autonomy and remote teleoperation introduce risks independently, but those risks may be compounded when both capabilities are present in the same system. There are also sensor or imaging data integrity risks, where systems are reliant on data to see and act. The FDA has identified cybersecurity considerations in previous guidance and warns that devices/systems can be rendered nonfunctional due to cybersecurity incidents or design vulnerabilities, and availability must be maintained at both the control and procedural ends.
The FDA is looking at an end-to-end system perspective rather than the examination of isolated individual components to identify system-level threats. Authentication, integrity, and non-repudiation controls would need to be robust; otherwise, the accuracy of commands could not be guaranteed and confirmed as having been issued by authorized individuals. Another key consideration is threats that users at either end may not be able to see, such as if a video feed has been tampered with, which may not be apparent at a patient’s bedside, for example.
The FDA has asked 15 questions to guide discussion. “The questions posed throughout this paper are intended to solicit the perspectives, expertise, and practical experience of the broader stakeholder community,” explained the FDA. “FDA is seeking to develop a regulatory approach that would rigorously and appropriately mitigate risks while championing the meaningful benefits these technologies offer.” The FDA seeks feedback by January 5, 2027.
In addition to the discussion paper, the FDA is also hosting a hybrid two-day public workshop on December 2-3 to advance the understanding of autonomous and remote teleoperated robotic medical devices. Registration is required by November 23, 2026.
The post FDA Seeks Feedback on Risks from Autonomous/Remote Teleoperation Medical Devices appeared first on The HIPAA Journal.

